FI96316B - DNA som kodar för bFGF mutein, transformerad bakterie som innefattar nämnda DNA och förfarande för produktion av muteinet - Google Patents
DNA som kodar för bFGF mutein, transformerad bakterie som innefattar nämnda DNA och förfarande för produktion av muteinet Download PDFInfo
- Publication number
- FI96316B FI96316B FI880845A FI880845A FI96316B FI 96316 B FI96316 B FI 96316B FI 880845 A FI880845 A FI 880845A FI 880845 A FI880845 A FI 880845A FI 96316 B FI96316 B FI 96316B
- Authority
- FI
- Finland
- Prior art keywords
- mutated
- bfgf
- protein
- human bfgf
- ptb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
- C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (18)
1. Rekombinant DNA som har en bassekvens som kodar för ett muterat protein (mutein) av basisk fibroblast tillväxtfaktor (bFGF) innehällande 4 cysteiner, kännetecknadav att minst en cystein har ersatts med en annan neutral amino-syra och minst en aminosyra kan fattas frän bFGF:s aminotermal och/eller karboxiterminal/ varvid muteinerna har en aktivitet som förbättrar tillväxten av fibroblast, en aktivitet som stimulerar tillväxten av kapillära endotelceller eller en angiogenisk aktivitet.
2. Rekombinant DNA enligt patentkravet 1, känneteck-n a d av att sagda bFGF innefattar aminosyrasekvensen: Phe-Phe-Leu-Arg-Ile-His-Pro-Asp-Gly-Arg-Val-Asp-Gly-Val-Arg-Glu-Lys-Ser-Asp-Pro i sin molekyl
3. Rekombinant DNA enligt patentkravet 1, känneteck-n a d av att minst en cystein är ersatt med serin.
4. Rekombinant DNA enligt patentkravet 1, känneteck-n a d av att muteinet har serin i 70-ställning i human bFGF i stället för cystein.
5. Rekombinant DNA enligt patentkravet 1, känneteck-n a d av att muteinet har serin i 88-ställning i human bFGF i stället för cystein.
6. Rekombinant DNA enligt patentkravet 1, känneteck-n a d av att muteinet har serin i 70- och i 88-ställning i human bFGF i stället för cystein.
7. Transformerad bakterie som innefattar en vektor som inne-häller en rekombinant ’DNA med en bassekvens som kodar för ett 96316 muterat protein (mutein) av basisk fibroblast tillväxtfaktor (bFGF) innehällande 4 cysteiner, kännetecknad av att minst en cystein har ersatts med en annan neutral amino-syra och minst en aminosyra kan fattas fran bFGF: s aminotermal och/eller karboxiterminal, varvid muteinerna har en aktivitet som förbättrar tillväxten av fibroblast, en aktivitet som stimulerar tillväxten av kapillära endotelceller eller en angiogenisk aktivitet.
8. Transformerad bakterie enligt patentkravet 7, kännetecknad av att sagda bFGF innefattar aminosyra- sekvensen: Phe-Phe-Leu-Arg-Ile-His-Pro-Asp-Gly-Arg-Val-Asp-Gly-Val-Arg-Glu-Lys-Ser-Asp-Pro i sin molekyl
9. Transformerad bakterie enligt patentkravet 7, k ä n n e-tecknadav att minst en cystein är ersatt med serin.
10. Transformerad bakterie enligt patentkravet 7, k ä n n e-tecknadav att den är E. coli DHl/^TB 742 (FERM BP- 1642) .
11. Transformerad bakterie enligt patentkravet 7, kännetecknad av att den är E. coli DH1/PTB 743 (FERM BP- 1643) .
12. Transformerad bakterie enligt patentkravet 7, k ä n n e-tecknadav att den är E. coli MM294/PTB 762 (FERM BP- 1645).
13. Förfarande för framställning av ett muterat protein (mutein) av basisk fibroblast tillväxtfaktor (bFGF) innehällande 4 cysteiner, i vilken minst en cystein har ersatts med en annan neutral’ aminosyra och minst en aminosyra kan I! • 96316 fattas frän bFGF:s aminotermal och/eller karboxiterminal, varvid muteinerna har en aktivitet som förbättrar tillväxten av fibroblast, en aktivitet som stimulerar tillväxten av kapillära endotelceller eller en angiogenisk aktivitet, kännetecknat av att man odlar en transformerad mikro-organism som innefattar en vektor som innehäller en rekombinant DNA med en bassekvens som kodar för muteinet av basisk fibroblast tillväxtfaktor (bFGF) i ett odlingsmedium för att producera och accumulera muteinet i odlingslösningen.
14. Förfarande enligt patentkravet 13, känneteck- n a d av att sagda bFGF innefattar aminosyrasekvensen: Phe-Phe-Leu-Arg-Ile-His-Pro-Asp-Gly-Arg-Val-Asp-Gly-Val-Arg-Glu-Lys-Ser-Asp-Pro i sin molekyl
15. Förfarande enligt patentkravet 13, känneteck- n a d av att minst en cystein är ersatt med serin.
15. Förfarande enligt patentkravet 13, känneteck- n a d av att muteinet har serin i 70-ställningen i human bFGF i stället för cystein.
17. Förfarande enligt patentkravet 13, känneteck- n a d av att muteinet har serin i 88-ställningen i human bFGF i stället för cystein.
18. Förfarande enligt patentkravet 13, känneteck- n a d av att muteinet har serin i 70- och i 88-ställningen i human bFGF i stället för cystein.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4221887 | 1987-02-24 | ||
JP4221887 | 1987-02-24 | ||
JP4344487 | 1987-02-25 | ||
JP4344487 | 1987-02-25 | ||
JP8197787 | 1987-04-02 | ||
JP8197787 | 1987-04-02 | ||
JP14751187 | 1987-06-12 | ||
JP14751187 | 1987-06-12 | ||
JP20151087 | 1987-08-11 | ||
JP20151087 | 1987-08-11 | ||
JP29028387 | 1987-11-17 | ||
JP29028387 | 1987-11-17 | ||
JP1626088 | 1988-01-26 | ||
JP63016260A JP2526965B2 (ja) | 1987-02-24 | 1988-01-26 | ムテイン,dnaおよびその用途 |
Publications (4)
Publication Number | Publication Date |
---|---|
FI880845A0 FI880845A0 (sv) | 1988-02-23 |
FI880845A FI880845A (sv) | 1988-08-25 |
FI96316B true FI96316B (sv) | 1996-02-29 |
FI96316C FI96316C (sv) | 1996-06-10 |
Family
ID=27563743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI880845A FI96316C (sv) | 1987-02-24 | 1988-02-23 | DNA som kodar för bFGF mutein, transformerad bakterie som innefattar nämnda DNA och förfarande för produktion av muteinet |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0281822B1 (sv) |
JP (1) | JP2526965B2 (sv) |
KR (1) | KR960013574B1 (sv) |
CN (1) | CN1031893C (sv) |
AT (1) | ATE108829T1 (sv) |
AU (1) | AU613564B2 (sv) |
CS (1) | CS407691A3 (sv) |
DE (1) | DE3850690T2 (sv) |
DK (1) | DK173269B1 (sv) |
ES (1) | ES2056842T3 (sv) |
FI (1) | FI96316C (sv) |
IE (1) | IE64299B1 (sv) |
IL (1) | IL85473A (sv) |
NO (1) | NO180305C (sv) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852177A (en) * | 1987-02-24 | 1998-12-22 | Takeda Chemical Industries, Ltd. | Basic fibroblast growth factor (bFGF) muteins |
JPH03500529A (ja) * | 1987-06-18 | 1991-02-07 | モナシュ ユニバーシティ | 増殖因子 |
AU611614B2 (en) * | 1987-06-18 | 1991-06-13 | Monash University | Growth factors |
GB8821795D0 (en) * | 1988-09-16 | 1988-10-19 | Erba Carlo Spa | New derivatives of human/bovine basic fibroplast growth factor |
US5352589A (en) * | 1988-09-16 | 1994-10-04 | Farmitalia Carlo Erba S.R.L. | Deletion mutant of basic fibroblast growth factor and production thereof |
US5120715A (en) * | 1988-12-12 | 1992-06-09 | Takeda Chemical Industries, Ltd. | Method for purifying fibroblast growth factor protein |
US5464943A (en) * | 1989-04-26 | 1995-11-07 | Takeda Chemical Industries, Ltd. | DNA encoding glycosylated FGF and production thereof |
EP0394951A1 (en) * | 1989-04-26 | 1990-10-31 | Takeda Chemical Industries, Ltd. | Glycosylated bFGF and production thereof |
CA2020654A1 (en) * | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Stabilized fgf composition and production thereof |
WO1991009954A1 (en) * | 1989-12-27 | 1991-07-11 | Resnick Michael A | Novel system for isolating and producing new genes, gene products and dna sequences |
EP0507948A1 (en) | 1989-12-28 | 1992-10-14 | Takeda Chemical Industries, Ltd. | Monoclonal antibody, hybridomas, their production and use |
JPH047617A (ja) * | 1990-04-26 | 1992-01-13 | Canon Inc | 電子機器 |
US5612211A (en) * | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US5206354A (en) * | 1990-11-23 | 1993-04-27 | American Cyanamid Company | Dna sequence encoding active fragment of fibroblast growth factor, hbf-2 |
CA2056142A1 (en) | 1990-11-27 | 1992-05-28 | Hirotomo Masuya | Pyridopyridazine compounds and their use |
ATE139700T1 (de) * | 1991-02-15 | 1996-07-15 | Takeda Chemical Industries Ltd | Mit einem zellwachstumsfaktor bewirkte anregung von wachstum im knocheninneren |
EP0499990B1 (en) * | 1991-02-19 | 1996-05-15 | Takeda Chemical Industries, Ltd. | Method for producing cysteine-free peptides |
US5492894A (en) * | 1991-03-21 | 1996-02-20 | The Procter & Gamble Company | Compositions for treating wrinkles comprising a peptide |
TW209174B (sv) | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
JP3303211B2 (ja) * | 1991-04-26 | 2002-07-15 | 武田薬品工業株式会社 | bFGFムテインおよびその製造法 |
US5461029A (en) * | 1992-04-24 | 1995-10-24 | American Cyanamid Company | Method of treating herpes viral infections using HBNF and MK proteins |
US6805865B1 (en) * | 1993-05-27 | 2004-10-19 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
JPH07114789B2 (ja) * | 1993-08-26 | 1995-12-13 | 工業技術院長 | 上肢動作補助機構 |
JPH09503661A (ja) * | 1993-09-24 | 1997-04-15 | アメリカン シアナミド カンパニー | 繊維芽細胞成長因子の表面ループ構造アナログ |
JP2562413B2 (ja) * | 1993-11-04 | 1996-12-11 | 株式会社東京機械製作所 | 版胴における刷版装着装置 |
IT1269321B (it) * | 1994-04-15 | 1997-03-26 | Eniricerche Spa | Mutanti stabili della d-n- -carbamilasi |
US6274712B1 (en) | 1997-12-23 | 2001-08-14 | 3-Dimensional Pharmaceuticals, Inc. | Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137 |
NZ537072A (en) | 2002-06-18 | 2006-12-22 | Eisai Co Ltd | Primary cultured adipocytes for gene therapy to which a foreign gene has been transferred |
WO2007109312A2 (en) | 2006-03-20 | 2007-09-27 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
CN102690782A (zh) * | 2012-06-14 | 2012-09-26 | 安徽农业大学 | 一种成纤维细胞培养液 |
KR101610861B1 (ko) * | 2014-07-28 | 2016-04-11 | (주)케어젠 | 골분화 촉진능 및 치주인대섬유모세포 활성 촉진능을 갖는 펩타이드 및 이의 용도 |
CN105924532A (zh) * | 2016-06-08 | 2016-09-07 | 盘古基因生物工程(南京)股份有限公司 | 一种可溶性碱性成纤维细胞生长因子融合蛋白表达载体及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI82266C (sv) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Förfarande för framställning av IL-2 -mutein |
US4956455A (en) * | 1984-03-05 | 1990-09-11 | The Salk Institute For Biological Studies | Bovine fibroblast growth factor |
DE3689845T3 (de) * | 1985-09-12 | 2001-11-15 | Scios Inc | Rekombinanter fibroblast-wachstumsfaktor. |
WO1989000198A1 (en) * | 1987-07-07 | 1989-01-12 | Biotechnology Research Associates, J.V. | Recombinant fibroblast growth factors |
KR890701607A (ko) * | 1987-11-24 | 1989-12-21 | 원본미기재 | 섬유아세포 성장 인자의 유사체 |
-
1988
- 1988-01-26 JP JP63016260A patent/JP2526965B2/ja not_active Expired - Lifetime
- 1988-02-18 NO NO880719A patent/NO180305C/no not_active IP Right Cessation
- 1988-02-19 IL IL85473A patent/IL85473A/xx not_active IP Right Cessation
- 1988-02-20 ES ES88102491T patent/ES2056842T3/es not_active Expired - Lifetime
- 1988-02-20 AT AT88102491T patent/ATE108829T1/de not_active IP Right Cessation
- 1988-02-20 DE DE3850690T patent/DE3850690T2/de not_active Expired - Lifetime
- 1988-02-20 EP EP88102491A patent/EP0281822B1/en not_active Expired - Lifetime
- 1988-02-23 FI FI880845A patent/FI96316C/sv active IP Right Grant
- 1988-02-23 AU AU12085/88A patent/AU613564B2/en not_active Expired
- 1988-02-23 IE IE48288A patent/IE64299B1/en not_active IP Right Cessation
- 1988-02-23 DK DK198800926A patent/DK173269B1/da not_active IP Right Cessation
- 1988-02-24 KR KR88001949A patent/KR960013574B1/ko not_active IP Right Cessation
- 1988-02-24 CN CN88100913A patent/CN1031893C/zh not_active Expired - Lifetime
-
1991
- 1991-12-27 CS CS914076A patent/CS407691A3/cs unknown
Also Published As
Publication number | Publication date |
---|---|
DE3850690T2 (de) | 1995-01-05 |
EP0281822A3 (en) | 1990-03-21 |
IE64299B1 (en) | 1995-07-26 |
DK92688D0 (da) | 1988-02-23 |
CN88100913A (zh) | 1988-09-07 |
EP0281822B1 (en) | 1994-07-20 |
KR880010130A (ko) | 1988-10-07 |
DK173269B1 (da) | 2000-05-29 |
ES2056842T3 (es) | 1994-10-16 |
FI880845A0 (sv) | 1988-02-23 |
DE3850690D1 (de) | 1994-08-25 |
NO880719L (no) | 1988-08-25 |
EP0281822A2 (en) | 1988-09-14 |
AU1208588A (en) | 1988-08-25 |
CN1031893C (zh) | 1996-05-29 |
AU613564B2 (en) | 1991-08-01 |
ATE108829T1 (de) | 1994-08-15 |
FI96316C (sv) | 1996-06-10 |
JP2526965B2 (ja) | 1996-08-21 |
CS407691A3 (en) | 1992-06-17 |
IL85473A (en) | 1997-03-18 |
NO180305B (no) | 1996-12-16 |
KR960013574B1 (en) | 1996-10-09 |
DK92688A (da) | 1988-08-25 |
IE880482L (en) | 1988-08-24 |
FI880845A (sv) | 1988-08-25 |
NO180305C (no) | 1997-03-26 |
JPH02193A (ja) | 1990-01-05 |
NO880719D0 (no) | 1988-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI96316B (sv) | DNA som kodar för bFGF mutein, transformerad bakterie som innefattar nämnda DNA och förfarande för produktion av muteinet | |
EP0335243B1 (en) | Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression | |
US5750654A (en) | Leukaemia inhibitory factor | |
EP0503297B1 (en) | GLIA activating factor and its production | |
JPH01501283A (ja) | 新規な型のコロニー刺激因子―1 | |
US5851990A (en) | bFGF mutein and its production | |
NZ245047A (en) | Hybrid transforming growth factor and recombinant dna encoding such a hybrid | |
JPH01501361A (ja) | 新しいt細胞サプレッサー因子の生産およびその用途 | |
EP0326907A1 (en) | Polypeptide, DNA and its use | |
US5858779A (en) | Monoclonal antibody, hybridoma, their production and use thereof | |
US5886141A (en) | Smooth muscle mitogen peptides and DNA coding therefor | |
US5852177A (en) | Basic fibroblast growth factor (bFGF) muteins | |
EP0421455B1 (en) | A mutein of HST-1 and production thereof | |
EP0555785B1 (en) | Smooth muscle mitogen and DNA coding therefor | |
JP2832354B2 (ja) | ムテイン,dnaおよびその用途 | |
US5981197A (en) | Monoclonal antibody, hybridoma, their production and use thereof | |
JP2779621B2 (ja) | モノクローナル抗体,ハイブリドーマ,それらの製造法およびそれらの用途 | |
HU204089B (en) | Process for producing muteins of bfgf | |
JP3127246B2 (ja) | ポリペプチド,dnaおよびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB | Publication of examined application | ||
FG | Patent granted |
Owner name: TAKEDA CHEMICAL INDUSTRIES, LTD. |